tbuckley/cabot-search huggingface dataset:
An Accidental Nutritionist
Authors: Alfred Sommer
Journal: Annual Review of Nutrition (2020)

My career as an accidental nutritionist began with my immersion in cholera control, a cyclone disaster, a smallpox epidemic, and formal training in ophthalmology and epidemiology. Interest in blindness prevention inexplicably led me to (re)pioneer the effects, treatment, and prevention of vitamin A deficiency, while faced with intense criticism by many leading scientists in the nutrition community. The resulting efforts by the World Health Organization and UNICEF in support of programs for the global control of vitamin A deficiency still face vocal opposition by some senior scientists, despite having been estimated to have saved tens of millions of children from unnecessary death and blindness. This entire journey was largely an accident!
1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses
Authors: S.M. Gadgeel, M. Yan, S.M. Paul, M. Mathisen, S. Mocci, Z.J. Assaf, R. Patel, E.S. Sokol, T. Mok, S. Peters, L. Paz-Ares, R. Dziadziuszko
Journal: Annals of Oncology (2020)
Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States
Authors: Christian Lee-Rodriguez, Paul Y. Wada, Yun-Yi Hung, Jacek Skarbinski
Journal: JAMA Network Open (2020)

Active tuberculosis (TB) disease leads to substantial mortality but is preventable through screening and treatment for latent TB infection. Early mortality after TB diagnosis (≤1 year) is well described, but delayed mortality (>1 year) among patients with active TB is poorly understood.To compare early and delayed mortality and years of potential life (YPL) lost among patients with active TB disease vs an age-, sex-, and year of diagnosis-matched comparison cohort without active TB disease.This retrospective cohort study, conducted in the integrated health system of Kaiser Permanente Northern California, included patients with microbiologically confirmed active TB disease from January 1, 1997, to December 31, 2017, and a control cohort matched by age, sex, and year of diagnosis. Multivariable models were used to adjust for demographic and clinical characteristics. Patients with active TB disease prior to 1997 were excluded. Data were analyzed from January 1, 2019, to January 31, 2020.Microbiologically confirmed TB disease.Early (≤1 year after TB diagnosis) and delayed (>1 year after TB diagnosis) all-cause mortality.A total of 2522 patients who had active TB from 1997 to 2017 were identified, with 17 166 person-years of follow-up. The comparison cohort included 100 880 persons with 735 726 person-years of follow-up. In the active TB and comparison cohorts, similar percentages of persons were male (56.3% vs 55.6%), aged 45 to 64 years (33.7% vs 33.7%), and aged 65 years or older (24.7% vs 24.7%). Both early mortality (7.0%) and delayed mortality (16.3%) were higher among patients with active TB disease compared with those without active TB disease (1.1% and 12.0%, respectively). Patients with active TB disease had a significantly higher risk for early (adjusted hazard ratio [aHR], 7.29; 95% CI, 6.08-8.73) and delayed (aHR, 1.78; 95% CI, 1.61-1.98) mortality compared with the comparison cohort (P < .001). Active TB disease was associated with an adjusted -7.0 (95% CI, -8.4 to -5.5) YPL lost compared with the comparison cohort.In this study, patients with active TB disease had significantly higher early and delayed all-cause mortality when adjusting for demographic and clinical characteristics. These findings suggest that TB prevention through screening and treatment of latent TB infection could reduce mortality and YPL lost due to active TB disease.
1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: M. Burotto, E. Felip, Z. Zvirbule, L.A. Herraez Baranda, P. Chanu, S. Kshirsagar, V. Maiya, E. Pozzi, E. Restuccia
Journal: Annals of Oncology (2020)
1874P Impact of infections and antibiotic therapy in a cohort of patients with advanced solid cancers who receive immune checkpoints inhibitors. An observational, retrospective study
Authors: C. Esteban Esteban, E. Martínez Moreno, K.A. Martínez Barroso, M. Borregón Rivilla, I. Ramos Reguera, A.M. Ramos Garrido, J.M. Andrade Santiago, L. Fernández Franco, I. García Carbonero, R. Álvarez Cabellos, J. Medina Martínez, J.I. Chacón López-Muñiz, J.D. Cárdenas, B. Berzal Hernández, M.A. Mazariegos Rubi, A.K. Santos Rodríguez
Journal: Annals of Oncology (2020)
514P Updated analysis of outcomes of elderly patients with resectable liver metastases from colorectal cancer (CRLM): Single center experience
Authors: R. Nassabein, None L. mansour, F. Vandenbroucke-Menu, F. Aubin, J-P. Ayoub, M. Dagenais, R. Lapointe, R. Letourneau, M. Plasse, A. Roy, S. Turcotte, M. Tehfe
Journal: Annals of Oncology (2020)
85MO Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH)
Authors: C. Benedikt Westphalen, F. André, S. Ganesan, V. Heinemann, E. Rouleau, A. Fine, L. Garcia Palacios, E.S. Sokol, M. Thomas, J. Mateo
Journal: Annals of Oncology (2020)
1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)
Authors: M. Faehling, C. Schumann, P. Christopoulos, P. Hoffknecht, J. Alt, M. Horn, S. Eisenmann, A. Schlenska-Lange, S.P. Aries, S. Sackmann, P. Schuett, F. Steger, D. Christoph
Journal: Annals of Oncology (2020)
619P Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network
Authors: A. Berruti, A. Mosca, S. Bianchi, V. Prati, C. Ortega, C. Buttigliero, E. Fea, P. Vanella, F. Valcamonico, G. Ciccone, Z. Sirotova, I. Chiappino, O. Dal Canton, C. Masini, C. Sacco†, D. Amoroso, F. Montagnani, A. Comandone, A. Gennari, M. Tucci
Journal: Annals of Oncology (2020)
1851P The added value of the H2 blocker ranitidine in premedication regimens during paclitaxel treatment
Authors: J.M. Cox, L. Van Doorn, R. Malmberg, E. Oomen-de Hoop, T.M. Bosch, P.M.L.A. van den Bemt, I.A. Boere, A. Jager, R.H. Mathijssen, R.W.F. van Leeuwen
Journal: Annals of Oncology (2020)
Ultrasonography Evaluation of Bilateral Focal Auricular Dyskinesia
Authors: Yiding Li, Kappaganthu V. Prasanna, Tze Chao Wee
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency
Authors: Paul Bastard, Jeremy Manry, Jie Chen, Jérémie Rosain, Yoann Seeleuthner, Omar AbuZaitun, Lazaro Lorenzo, Taushif Khan, Mary Hasek, Nicholas Hernandez, Benedetta Bigio, Peng Zhang, Romain Lévy, Shai Shrot, Eduardo J. Garcia Reino, Yoon-Seung Lee, Soraya Boucherit, Mélodie Aubart, Rik Gijsbers, Vivien Béziat, Zhi Li, Sandra Pellegrini, Flore Rozenberg, Nico Marr, Isabelle Meyts, Bertrand Boisson, Aurélie Cobat, Jacinta Bustamante, Qian Zhang, Emmanuelle Jouangy, Laurent Abel, Raz Somech, Jean-Laurent Casanova, Shen-Ying Zhang
Journal: Journal of Clinical Investigation (2020)

Inborn errors of TLR3-dependent IFN-α/β- and IFN-λ-mediated immunity in the CNS can underlie herpes simplex virus 1 (HSV-1) encephalitis (HSE). The respective contributions of IFN-α/β and IFN-λ are unknown. We report a child homozygous for a genomic deletion of the entire coding sequence and part of the 3'-UTR of the last exon of IFNAR1, who died of HSE at the age of 2 years. An older cousin died following vaccination against measles, mumps, and rubella at 12 months of age, and another 17-year-old cousin homozygous for the same variant has had other, less severe, viral illnesses. The encoded IFNAR1 protein is expressed on the cell surface but is truncated and cannot interact with the tyrosine kinase TYK2. The patient's fibroblasts and EBV-B cells did not respond to IFN-α2b or IFN-β, in terms of STAT1, STAT2, and STAT3 phosphorylation or the genome-wide induction of IFN-stimulated genes. The patient's fibroblasts were susceptible to viruses, including HSV-1, even in the presence of exogenous IFN-α2b or IFN-β. HSE is therefore a consequence of inherited complete IFNAR1 deficiency. This viral disease occurred in natural conditions, unlike those previously reported in other patients with IFNAR1 or IFNAR2 deficiency. This experiment of nature indicates that IFN-α/β are essential for anti-HSV-1 immunity in the CNS.
1064P Efficacy of a novel anti-CEACAM1 monoclonal antibody and CEACAM1 up-regulation in tumour-infiltrating lymphocytes (TILs) of cancer patients
Authors: H.J. Cho, J-C. Lee, H-Y. Park, W.S. Yang, H-M. Nam, J.H. Ryu, Y. Oh, M. Hur
Journal: Annals of Oncology (2020)
1665P Prognostic factors in pediatric rhabdomyosarcoma: A 20-year single-institution experience
Authors: D. Tajina-Abdelmaksoud, F. Letaief-Ksontini, S. Yahiaoui, A. Gabsi, M. Saadi, N. Chraiet, C. Nasr, A. Mezlini
Journal: Annals of Oncology (2020)
1752P Epidemiological analysis of SARS-CoV-2 virus infection in patients with solid tumors: The experience of Infanta Sofía University Hospital (HUIS)
Authors: C. Gomez Raposo, S. Falagán, C. Andreu-Vázquez, I.J. Thuissard, C. García Fernández, C. Aguayo Zamora, A.M. Jiménez Gordo, M. López Gómez, M. Merino Salvador, C. Sandoval, M. Sereno Moyano, F. Zambrana, S. Roa Franco, C. Martín Domínguez, J. Moreno Rubio, E. Casado
Journal: Annals of Oncology (2020)
1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
Authors: J. Mazieres, P. Tomasini, A. Lusque, M. Boucekine, O. Gautschi, A.B. Cortot, S. Couraud, A. Thai, T. Ng, L. Greillier, R. Veillon, J.W. Neal, S. Popat, V. Gounant, L. Mhanna, A. Drilon, J. Milia Baron, F. Barlesi
Journal: Annals of Oncology (2020)
507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer
Authors: A. Sartore-Bianchi, F.M. Tosi, F. Bergamo, A. Amatu, S. Ghezzi, C. Martino, E.F. Bonazzina, K. Bencardino, E. Fenocchio, G. Mauri, A. Ardizzoni, V. Torri, E. Valtorta, E. Bonoldi, A. Vanzulli, D. Regge, F. Ciardiello, V. Zagonel, S. Marsoni, S. Siena
Journal: Annals of Oncology (2020)
Current Epidemiological Trends in Firearm Mortality in the United States
Authors: Jason E. Goldstick, Patrick M. Carter, Rebecca M. Cunningham
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Strengthening the UK primary care response to covid-19
Authors: Sophie Park, Josephine Elliott, Anita Berlin, Julia Hamer-Hunt, Andy Haines
Journal: BMJ (2020)

Health services across the world made rapid adjustments to the direct and indirect consequences of covid-19 with varying success. 1 The World Health Organization's initial recommendations were based on system adaptations in China, focusing predominantly on secondary care and public health. 2 3Primary care received less policy attention both globally and in the UK.Hospitals were major centres of transmission, with mortality at 40% among those receiving critical care 4 and many patients dying alone.With cases again increasing, there is an urgent need for strategies to support management of patients at home, reduce unnecessary admissions, and optimise the use of health service resources.
1707P CureCancer digital tool in the routine clinical oncology practice facilitates PROs, communicating with HCPs, treatment adherence and “distancing interventions” during COVID-19 and reduces costs: A feasibility and satisfaction study
Authors: D. Galiti, S. Agelaki, A. Karampeazis, H. Linardou, N. Tsoukalas, E. Arvanitou, E. Georgopoulou, C. Vallilas, K. Syrigos, S. Sgourou, S. Kokkali-Zervos, E. Stamatogianni, A. Boutis, A.N. Christopoulou, L. Kontovinis, A. Mala, G. Rigas, Z. Saridaki-Zoras, O. Nicolatou-Galitis, I. Boukovinas
Journal: Annals of Oncology (2020)
Disturbed Flow Induces Atherosclerosis by Annexin A2-Mediated Integrin Activation
Authors: Catherine Demos, Darian Williams, Hanjoong Jo
Journal: Circulation Research (2020)

therosclerosis is a chronic inflammatory disease, occurring preferentially in branches and curves in arteries exposed to disturbed blood flow (d-flow).In contrast, straight arteries are exposed to stable flow (s-flow) and are protected from atherosclerosis development. 1-3D-flow is characterized by low, oscillatory shear stress (OS) whereas s-flow is associated with unidirectional (either pulsatile or nonpulsatile) and relatively high level of laminar shear stress.Flow regulates these atherogenic responses by regulating gene expression and signaling pathways in endothelial cells (ECs).Mechanosensors (also known as mechanoreceptors) detect changes in shear stress direction and magnitude with respect to time in ECs.Once detected, the mechanosensors convert the mechanical force into biochemical signals, triggering cell signaling pathways, and changes in cell functions.D-flow induces, while s-flow prevents, endothelial dysfunction including inflammation, endothelial-mesenchymal transition, thrombosis, vasoconstriction, and barrier dysfunction, which in turn lead to atherosclerosis in conjunction with additional risk factors such as hypercholesterolemia. 1,4 While these flow-dependent changes are relatively well described, the cell and molecular mechanisms by which d-flow and s-flow induce these different endothelial responses are still unclear.Are there specialized mechanosensors that detect d-flow versus s-flow, or does one mechanosensor respond differently to different flow conditions?In the current edition of Circulation Research, Zhang et al define a novel molecular mechanism by which d-flow induces inflammation and atherosclerosis by activating integrin α5 through interaction with ANXA2 (annexin A2) by a Piezo1-dependent mechanism.
1471P 3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients
Authors: M. Cabeza, F. Papaccio, M.F. Gutierrez Bravo, V. Gambardella, C. Alfaro-Cervello, C. Martínez-Ciarpaglini, Z. Garzón-Lloría, P. Rentero-Garrido, S. Zúñiga-Trejos, E. Seda-García, F. Gimeno-Valiente, A. Peña, M. Barrios, N. Tarazona, D. Roda, A. Cervantes, T. Fleitas, J. Castillo
Journal: Annals of Oncology (2020)
Getting to the point in point-of-care diagnostics for tuberculosis
Authors: Elisa H. Ignatius, Keira A. Cohen, William R. Bishai
Journal: Journal of Clinical Investigation (2020)

Tuberculosis (TB) continues to affect over 10 million people per year worldwide. Despite advances in diagnosis, smear microscopy insufficiently detects pulmonary disease, with test result reporting taking longer than a day. While urine assays to detect the lipopolysaccharide lipoarabinomannan (LAM), present in mycobacterial cell walls, can provide results within minutes, the currently available assay has low sensitivity and its application is limited to patients with HIV suspected of having TB. In this issue of the JCI, Broger and Nicol et al. investigated 3 rapid urine tests in 372 ambulatory HIV-negative individuals suspected of having TB in South Africa and Peru. FujiLAM emerged as a rapid test to confirm TB diagnosis in the HIV-seronegative population. This study shows that FujiLAM has considerable potential to reshape the TB diagnostics landscape, making diagnosis and treatment in one office visit a reality for TB.
1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
Authors: D. Pesántez, F. Brasó-Maristany, F. Esposito, H.K. Oberoi, H. Oliveres, T. Pascual, M. Cuatrecasas, C. Teixido Febrero, E. Sanfeliu, J.C. Laguna, E. Seguí, A. Pérez, D. Martínez, J. Guerrero, S. López, G. Fernández-Esparrach, D. Momblán, C. Fillat, A. Prat, T. Sauri
Journal: Annals of Oncology (2020)
128P Exploratory analysis of the prognostic value of rotational thromboelastometry in colorectal cancer
Authors: A. Koumarianou, J. Moreno-Duran, E. Merkouri, K. Kampoli, A. Ntavatzikos, M. Manimani, I. Kotsantis, A. Psyrri, A. Travlou, E. Kyriakou
Journal: Annals of Oncology (2020)
1867P Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents: A real-world cross-sectional study from Switzerland (SAKK 95/16)
Authors: K. Ribi, B.J.K. Thuerlimann, C. Schär, D. Dietrich, R. Cathomas, U. Zuerrer, T. Von Briel, S. Anchisi, P. Bohanes, V. Blum, P. von Burg, M. Mannhart, C.B. Caspar, R. von Moos, M.T. Mark
Journal: Annals of Oncology (2020)
1465P A nationwide population-based study comparing treatment patterns and outcomes in synchronous versus metachronous metastatic esophageal and gastric adenocarcinoma
Authors: M. Pape, P.A.J. Vissers, D. Bertwistle, L. McDonald, H.W.M. van Laarhoven, R.H. Verhoeven
Journal: Annals of Oncology (2020)
598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours
Authors: J.J. Luke, F. Janku, J. Strauss, A.J. Olszanski, K. Leach, I. Radhakrishnan, A. Abbas
Journal: Annals of Oncology (2020)
1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)?
Authors: C. Linossi, I.G. Funingana, M. Petruzzelli, B.H. Rala de Paula, M. O'Donovan, M. Andrea, S. Hewitt, A.L. Williams, N. Grehan, A. Redmond, E.C. Smyth, R.D. Baird, E.M. Godfrey, M. Di Pietro, I. Faull, S. Dovedi, R.C. Fitzgerald, S. Pacey
Journal: Annals of Oncology (2020)
397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
Authors: E. Martinelli, G. Martini, T. Troiani, F. Pietrantonio, A. Avallone, N. Normanno, A. Nappi, E. Maiello, A. Falcone, G. Santabarbara, C. Pinto, D. Santini, D. Ciardiello, M. Terminiello, C. Borrelli, S. Napolitano, D. Renato, V. Famiglietti, L. Esposito, F. Ciardiello
Journal: Annals of Oncology (2020)
74P Targeting mitochondria as a novel therapeutic strategy in biliary tract cancer
Authors: P. Carotenuto, A. Barbato, A. Indrieri, M. Volpe, P. Quadrano, S. Brillante, S. Riccardo, L. Mirante, D. Cacchiarelli, I. Antonella, B. Franco, M. Salatiello, G. Troncone, L. Reggiani Bonetti, M. Dominici, M. Salati
Journal: Annals of Oncology (2020)
1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery
Authors: R. Shah, L.V. Klotz, M. Feißt, M. Schneider, M. Kriegsmann, M. Ried, C. Wesseler, D.C.C. Christoph, M. de Wit, J. Jürgens, H-G. Kopp, T. Wehler, M. Reck, S. Sackmann, C. Waller, N. Reinmuth, H. Bischoff, H. Winter, M. Eichhorn, M. Thomas
Journal: Annals of Oncology (2020)
1396P Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study
Authors: P. Boudou Rouquette, J. Arrondeau, C. Gervais, A. Jouinot, E. Fabre, S. De Percin, A-C. Piketty, C. Vaquin Villeminey, N. Al-Rassy, G. Ulmann, D. Damotte, A. Lupo-Mansuet, K. Leroy, F. Giraud, J. Alexandre, M. Alifano, L. Cynober, M. Wislez, J-P. Durand, F. Goldwasser
Journal: Annals of Oncology (2020)